glp 1 landscape Market Overview: GLP-1 Agonists and the Obesity Market | Blog The Growing GLP-1 Market Landscape

Copper Tripeptide-3, also called AHK-Cu, is synthetic

Back US FDA (Dec 2017) 'Drug Trial Snapshot: Ozempic'

In March 2024, the FDA approved semaglutide (Wegovy) not just for weight loss but also to reduce cardiovascular risk in adults with known heart disease

Anti-Aging: Packed with antioxidants and skin-renewing ingredients, the serum helps combat signs of aging, such as fine lines and wrinkles, for a more youthful-looking appearance

Published online 2025

Side Effect Profile Comparison The side effect profile of compounded GLP-1 medications is generally expected to be similar to brand-name versions because the side effects are driven primarily by the active ingredients mechanism of action, not by formulation-specific factors